Analysts Offer Insights on Healthcare Companies: PDL BioPharma (NASDAQ: PDLI), Aerie Pharma (NASDAQ: AERI) and Regulus (NASDAQ: RGLS)By Carrie Williams
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PDL BioPharma (NASDAQ: PDLI), Aerie Pharma (NASDAQ: AERI) and Regulus (NASDAQ: RGLS).
PDL BioPharma (NASDAQ: PDLI)
“Q3 revenue of $53.6MM was above consensus of $50.7MM but represents a 57%.”
According to TipRanks.com, Nadeau is a 1-star analyst with an average return of -3.1% and a 34.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Catabasis Pharmaceuticals, and Voyager Therapeutics Inc.
PDL BioPharma has an analyst consensus of Hold.
Aerie Pharma (NASDAQ: AERI)
According to TipRanks.com, Davis is ranked 0 out of 5 stars with an average return of -5.9% and a 32.1% success rate. Davis covers the Healthcare sector, focusing on stocks such as Aquinox Pharmaceuticals, Infotek Pharmaceuticals, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on Aerie Pharma is Strong Buy and the average price target is $51.50, representing a 56.8% upside.
In a report issued on November 1, Aegis Capital also initiated coverage with a Buy rating on the stock with a $63 price target.
Regulus (NASDAQ: RGLS)
In a report released yesterday, Christopher James from FBR Capital reiterated a Buy rating on Regulus (NASDAQ: RGLS), with a price target of $9. The company’s shares opened today at $2.45, close to its 52-week low of $2.44.
“After the close on November 1, Regulus Therapeutics reported its 3Q16 financial performance and held a conference call to provide an update on its clinical development. On the call, management indicated that the main focus for the quarter was further advancement of the RG-012 program, as well as potential resolution of the RG-101 clinical hold. Recall, RG-101 is in development for the treatment of hepatitis C virus (HCV) and was placed on clinical hold in late June 2016 following two cases on jaundice (see our previous note). We provide the following three key takeaways from yesterday’s call: (1) the time line for the resolution of the clinical hold on RG-101 was pushed out to 1Q17; (2) focus shifts to the multiple ascending dose (MAD) study with RG-012, while the HERA Phase II study in patients with Alport syndrome is paused; and (3) we expect strong presence at two major scientific meetings before the end of the year.”
According to TipRanks.com, James is ranked 0 out of 5 stars with an average return of -25.2% and a 19.6% success rate. James covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Aviragen Therapeutics, Inc., and Achillion Pharmaceuticals.
Currently, the analyst consensus on Regulus is Strong Buy and the average price target is $9, representing a 267.3% upside.
In a report released yesterday, Needham also reiterated a Buy rating on the stock with a $9 price target.